Special 5/2013

  • Biocapital

    In this issue:

    Good biocapital access – for a few

    In an era when payers are increasingly also looking at the economic benefits a new therapeutic has to offer, biotechs have to prove not only safety and efficacy to regulators, but cost-effectiveness to reimbursers as well. Both factors are subject to due dilligence when it comes time to apply for financing. That's why convincing investors of the value of product portfolios – which are most often developed by biotech innovators – has become a complex task. Market forecasts by Prime Therapeutics/Blue Cross-Blue Shield predict specialty drugs will account for 50% of all drug costs by 2018 (up from 20% in 2009). But the most current Global Biotech Report released by Ernst & Young at the end of April says despite that promising future, just a few large biotechs are benefiting from financing.

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/spezial/2013/5.html

Kurszettel

Alle Kurse

TOP

  • WILEX2.69 EUR14.47%
  • BAYER112.70 EUR6.17%
  • CO.DON3.32 EUR5.40%

FLOP

  • SYNGENTA310.90 CHF-1.96%
  • SANTHERA88.05 CHF-1.23%
  • ADDEX3.10 CHF-0.96%

TOP

  • CO.DON3.32 EUR32.8%
  • PAION3.05 EUR26.6%
  • EPIGENOMICS3.83 EUR23.2%

FLOP

  • ADDEX3.10 CHF-23.8%
  • EVOTEC3.08 EUR-15.8%
  • MEDIGENE3.93 EUR-14.6%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR286.0%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • BIOFRONTERA2.20 EUR-39.7%
  • MERCK KGAA68.48 EUR-39.7%

No liability assumed, Date: 19.09.2014